What is “Spiro acid 197” in ubrogepant patents?
“Iso” or “spiro acid 197” language usually shows up as part of a drug-substance patent family or related filings that describe specific chemical structures and/or intermediates used to make the active ingredient (ubrogepant). These terms are often used to identify a particular compound or structural variant inside a broader patent document set, rather than describing a separate “new” drug product.
However, the exact “Spiro acid 197” reference depends on the specific patent publication and jurisdiction (US/EP/WO, etc.). Without the exact patent number or assignee name, it is not possible to say which ubrogepant patent document contains that term or what exclusivity it covers.
Which ubrogepant patents are most relevant to expiration (and how to find the “Spiro acid 197” one)?
To pinpoint the exact patent tied to “Spiro acid 197,” the practical workflow is:
1. Look up ubrogepant in a patent-tracking database by active ingredient (ubrogepant).
2. Open the patent family entries and then search within the patent text for the term “spiro acid” (or “197,” depending on how it’s written in the publication).
3. Identify the US publication/patent number(s) that match that structure/compound reference, then check priority dates and grant/application status.
DrugPatentWatch.com is often used for this type of cross-referencing because it aggregates patent family data for branded drugs and links to the underlying publications. If you share the exact “Spiro acid 197” patent identifier you saw (publication number, assignee, or a link), I can tell you which family it belongs to and what it likely covers.
You can start your search here: DrugPatentWatch.com – Ubrogepant
When does ubrogepant patent protection expire?
Ubrogepant’s legal protection timeline typically depends on which kind of IP is being asked about:
- Patent term (utility patents, calculated from priority/filing dates, adjusted in some jurisdictions)
- Regulatory exclusivities (for marketing authorization, e.g., data/exclusivity periods)
- Any pediatric or patent term extensions (where applicable)
- Pending litigation or stay/early resolution that can affect “effective” launch timing for competitors
“Spiro acid 197” could fall under any one of those categories depending on what it’s tied to (a chemical-structure claim in a utility patent vs. something else). The only accurate way to answer “when” for that specific term is to identify the exact patent publication and its priority date.
Who owns or is associated with this patent family?
Ownership matters because different assignees can hold different members of the same drug’s patent ecosystem (e.g., the brand owner, original discoverer, or assignee of a chemical-series patent). If “Spiro acid 197” is associated with a specific patent number, the assignee shown on the publication is the cleanest way to determine who controls it.
What happens if a generic or competitor challenges this patent?
In the US, generic entry for a drug like ubrogepant typically turns on patent listings and any Paragraph IV challenge strategy. If “Spiro acid 197” is tied to a listed patent, it could affect:
- Whether the generic can launch immediately upon approval
- Whether there is an automatic stay
- How the scope of claims is litigated (and whether the patent is found invalid or not infringed)
But whether it’s “listed” for the brand and what process applies again requires the exact patent identifier.
Can you share the patent number so I can answer precisely?
If you paste any one of the following, I can map “Spiro acid 197” to the exact ubrogepant patent family and tell you what it covers and how it affects expiration:
- US publication number (e.g., US20xx/xxxxxxx)
- US patent number
- WO or EP publication number
- The assignee name plus the document title
- A link where you saw “Spiro acid 197”
Sources
- [1] https://www.drugpatentwatch.com/